HCPCS Level II code J9035 describes an injection of bevacizumab, 10 mg intended as an oncology biologic drug preparation for intravenous administration; the service is a therapeutic chemotherapy/biologic infusion typically provided in an outpatient infusion center or hospital outpatient department for treatment of cancers where bevacizumab is indicated.

For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only), Antibody-Drug Conjugates.